Novartis on What Great CDMO Partnerships Actually Look Like

About this episode

Isabel Feuerstein and Mark Schiefermeier discuss the foundations of high-performing CDMO relationships and Novartis' strategy for the future of biologics.

“Don’t pick a CMO that just agrees with you.” Isabel Feuerstein is Head of Business Development for EU and Asia CMO at Novartis, where she shapes the company’s contract manufacturing strategy across key global markets. Mark Schiefermeier leads the manufacturing unit at DS Schaftenau, one of Novartis’ critical drug substance manufacturing facilities in Austria, overseeing technical execution and quality systems that underpin Novartis’ external manufacturing commitments. In this episode of the PharmaSource podcast, Isabel and Mark explain why technical credibility, real transparency, and a willingness to challenge clients are the foundations of a high-performing CDMO relationship — and how Novartis is positioning its CMO business for the future of biologics. Read more .

People in this episode

Guests: Isabel Feuerstein, Mark Schiefermeier

Topics covered

• CDMO partnerships
• contract manufacturing
• biologics
• transparency
• technical credibility

Keywords

• CDMO
• contract manufacturing
• biologics
• transparency
• technical credibility
• Novartis
• drug substance

Mentioned in this episode

Organizations: Novartis, DS Schaftenau

Places: Austria

More episodes of PharmaSource Podcast

• How Sanofi Navigates Regulatory CMC Across Global Markets: Insights from Manda Pasarkar · June 11, 2026 · 31 min
• The Politics Behind the Pipeline: How MFN Pricing and Tariffs Are Reshaping Pharma's Global Strategy · June 8, 2026 · 18 min
• How to Build a Resilient Global Vaccine Supply Chain: From Crisis to Capability · June 4, 2026 · 46 min
• How Lonza Is Outgrowing the CDMO Market with Bioconjugation, AI, and Regionalization · May 31, 2026 · 29 min
• The Strategic Partnership Gap: Why CDMOs Are Meeting Pharma's Expectations Less Than Half the Time with Simon-Kucher · May 27, 2026 · 26 min
• Creative Financing Strategies for Biotech's Bear Market, Beyond the VC Round · May 25, 2026 · 29 min